Protein Glycosylation Influences Soluble Urokinase Plasminogen Activator Receptor (suPAR) Measurements

Elevated plasma levels of the biomarker soluble urokinase plasminogen activator receptor (suPAR) are prognostic adverse outcomes in cardiovascular disease (CVD). This novel inflammatory protein has five known N-linked glycosylation sites, but contribution to progression is unknown. study aimed assess impact on suPAR measurements. Bio-banked samples from healthy volunteers and patients with CVD were treated deglycosylation enzymes. was measured for all untreated using Virogates suPARnostic ELISA. Percentage change concentrations following treatment compared paired t-test, differences between patient cohorts examined Mann-Whitney test. In subjects, increased after pre-treatment enzymes (median 1.8 vs 2.4 ng/mL; p<0.001; n=15). diagnosed myocardial infarction (MI), a percentage increase also obtained treatment, this increment higher than acute chest pain without MI (58% 44%; p=0.02; decompensated heart failure, observed deglycosylation, that subjects (38% 30%; p=0.04; n=33). immunoreactivity ViroGates ELISA removal glycosylation, as demonstrated by treatment. suggests current clinical assay influenced its glycosylation. As alterations associated CVD, further investigations required implication respect accuracy progression.